Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) EPS (Weighted Average and Diluted): 2012-2024

Historic EPS (Weighted Average and Diluted) for Ascendis Pharma A (ASND) over the last 13 years, with Dec 2024 value amounting to -$7.07.

  • Ascendis Pharma A's EPS (Weighted Average and Diluted) fell 38.11% to $1.17 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.44, marking a year-over-year decrease of 47.26%. This contributed to the annual value of -$7.07 for FY2024, which is 23.17% up from last year.
  • According to the latest figures from FY2024, Ascendis Pharma A's EPS (Weighted Average and Diluted) is -$7.07, which was up 23.17% from -$9.20 recorded in FY2023.
  • In the past 5 years, Ascendis Pharma A's EPS (Weighted Average and Diluted) registered a high of $9.45 during FY2020, and its lowest value of -$10.61 during FY2022.
  • Over the past 3 years, Ascendis Pharma A's median EPS (Weighted Average and Diluted) value was -$9.20 (recorded in 2023), while the average stood at -$8.96.
  • Per our database at Business Quant, Ascendis Pharma A's EPS (Weighted Average and Diluted) surged by 102.02% in 2020 and then tumbled by 184.70% in 2021.
  • Over the past 5 years, Ascendis Pharma A's EPS (Weighted Average and Diluted) (Yearly) stood at $9.45 in 2020, then plummeted by 184.70% to -$8.01 in 2021, then slumped by 32.50% to -$10.61 in 2022, then climbed by 13.30% to -$9.20 in 2023, then rose by 23.17% to -$7.07 in 2024.